latanoprost / Generic mfg. - LARVOL DELTA

Retrospective analysis of the influence of prior treatment type on tolerability characteristics of NET/LAT and BIM/TIM using data from the MERCURY 3 study in patients with open-angle glaucoma and OHT (SOE 2025) - "Purpose: A post hoc analysis compared the tolerability characteristics of netarsudil 0.02%/latanoprost 0.005% (NET/LAT) and bimatoprost 0.03%/timolol 0.5% (BIM/TIM) in patients with glaucoma or ocular hypertension (OHT), stratified by either prior IOP-lowering monotherapy (pM) or combination therapy (pCT) before enrolment. MERCURY-3 study data were analysed retrospectively for the rate of treatment-emergent adverse events (TEAEs) and withdrawals due to adverse events (AEs), as well as the incidence of conjunctival hyperaemia (CH) and corneal verticillata (CV). NET/LAT pts with pM had a somewhat lower incidence of overall TEAEs and of CH, compared with those with pCT. This might contribute to a statistically significantly lower AE-attributed withdrawals. The results suggest that more complex or aggressive IOP-lowering therapy before the introduction of NET/LAT may be causally related to the incidence of clinically significant TEAEs in glaucoma and ocular hypertensive..."

Retrospective data • Glaucoma • Ophthalmology

Clinical findings and medical therapy for unilateral uveal effusion syndrome (UES) in posterior microphthalmos: a case report (SOE 2025) - "The patient received latanoprost (0.005% twice a day) and oral prednisolone 40 mg/day in a rapid tapering fashion. UES is a rare disease of unknown etiology characterized by uveal effusion and SRD. The standard treatment for UES has been surgery. Increased choroidal thickening as depicted by enhanced depth imaging OCT and dilated choroidal vessels with a perivascular leakage noticed by ICGA in previous literature reports might indicate the existence of choroidal vascular inflammation which might explain the positive effect of corticosteroids employment in this rare pathology."

Case report • Clinical • Macular Edema • Ophthalmology

Latanoprost versus fixed combination of tafluprost and timolol in patients with primary open-angle glaucoma (SOE 2025) - "The absolute mean IOP reduction from baseline at six months is statistically significant in LP or FCTT treatment. Compared to FCTT, 0.005% latanoprost administered once daily has a more significant IOP-lowering effect and safety for up to six months."

Clinical • Glaucoma • Ophthalmology

Acute Angle-Closure Glaucoma in a 4-Year-Old: A Rare Presentation of Idiopathic Uveitis with Severe Structural Complications (SOE 2025) - "Postoperative treatment included oral acetazolamide, timolol, latanoprost, and topical dexamethasone with cyclopentolate, normalizing IOP and reducing inflammation. Systemic corticosteroids and weekly methotrexate were initiated, with fortnightly 20 mg adalimumab added due to severity, in collaboration with pediatric rheumatology.Two months post-presentation, visual acuity improved to 0.5 (Snellen scale) in the right eye, with a quiet eye, clear cornea, minimal cells and flare, patent iridectomy, iris atrophy, and an IOP of 12 mmHg. This case highlights idiopathic uveitis as a significant pediatric condition that can acutely cause severe complications. Early multidisciplinary management is critical for preserving vision and preventing long-term damage."

Glaucoma • Ocular Inflammation • Ophthalmology • Uveitis

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: PolyActiva Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

0.005% Latanoprost Gel for Nonsegmental Vitiligo (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: Universitas Padjadjaran

New P2 trial • Dermatology • Immunology • Vitiligo

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. (PubMed, Adv Ther) - P2 | "In participants with POAG or OHT, mean 24-h IOP and nocturnal IOP at month 3 were consistently numerically lower with sepetaprost vs. latanoprost. Safety profiles were similar between groups."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Trends in anaesthesia for phacoemulsification combined with minimal invasive glaucoma surgery: a case report (Euroanaesthesia 2025) - "Moderate glaucoma damage with also moderate visual field damage, ocular pressure of 17 mmHg with daily use of latanoprost.Since it was the better eye, with moderate damage, performed peribulbar block (Ropivacaine 1%- 4mL) avoiding increases in intraocular pressure during anesthesia and admnistered dexmedetomidine for collaborative sedation 2 . Surgical procedure lasted 20 minutes, and patient was discharged consciously at same day, with ocular pressure already at 14 mmHg in the first few days. Anesthetic care during glaucoma micro-invasive ambulatorial anesthesia involves risk of transitory increase in intraocular pressure and damage to the optic nerve during local anesthetic injection. The goal of sedation must be minimize anxiety, and dexmedetomidine is an excellent option since provides an awake and cooperative sedation."

Case report • Clinical • Surgery • Anesthesia • Cataract • Glaucoma • Ophthalmology • Psychiatry

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: University of Maryland, Baltimore

Biomarker • New trial • Glaucoma • Ophthalmology

Developing a Chromatographic Method for Quantifying Latanoprost and Related Substances in Glaucoma Treatments. (PubMed, Pharmaceuticals (Basel)) - "The method can be reliably used to control the critical quality attributes of low-dose latanoprost products, ensuring their required high pharmaceutical quality, which translates into improvements in patient care. This advancement holds significant implications for enhancing the therapeutic management of glaucoma, ensuring drug safety and efficacy."

Journal • Glaucoma • Ophthalmology

Intraocular pressure is a promising target for myopia control. (PubMed, J Transl Med) - "Our findings highlight that pressure-dependent scleral remodeling contributes to the deceleration of AL elongation. These results underscore the efficacy of IOP reduction in mitigating the progression of myopia, providing a promising alternative strategy for myopia management."

Journal • Ophthalmology • Targeted Protein Degradation

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (clinicaltrials.gov) - P4 | N=70 | Recruiting | Sponsor: Prairie Eye Center | Not yet recruiting ➔ Recruiting

Enrollment open • Glaucoma • Ophthalmology

The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bulbous Keratopathy (PBK) (clinicaltrials.gov) - P=N/A | N=50 | Enrolling by invitation | Sponsor: University Hospital Dubrava

New trial • Glaucoma • Ophthalmology

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P2 | N=75 | Not yet recruiting | Sponsor: PolyActiva Pty Ltd

New P2 trial • Cardiovascular • Glaucoma • Ophthalmology

Investigating clues of cystoid macular edema from a vascular perspective under long-term latanoprost usage. (PubMed, Int Ophthalmol) - "This study demonstrates that latanoprost, the first prostaglandin analog known for its edema-inducing effect on the macula, does not have a long-term impact on macular vascularity. However, this result should be supported with longer and larger studies."

Journal • Glaucoma • Macular Edema • Ophthalmology

Aqueous Humor Dynamics Changes and Predictors of IOP Response to Latanoprost in Healthy Subjects. (PubMed, J Glaucoma) - "In healthy subjects, higher baseline IOP, lower uveoscleral outflow and higher BMI are predictors of a greater IOP reduction by latanoprost. A greater increase in uveoscleral outflow is responsible for this larger response."

Journal

Real-World pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database. (PubMed, Sci Rep) - "Among 38 drugs most frequently reported for conjunctivitis, two ophthalmic agents-brimonidine (ROR = 23.04) and latanoprost (ROR = 10.55)-and eight non-ophthalmic drugs, including tralokinumab (ROR = 83.3), dupilumab (ROR = 18.92), and allopurinol (ROR = 5.04), were associated with positive signals. Notably, ophthalmic agents had a significantly shorter induction period than non-ophthalmic drugs (mean 125.9 vs. 298.4 days). These findings underscore the need for vigilant pharmacovigilance and further investigation into the etiology and prevention of drug-related conjunctivitis."

Adverse events • Journal • Real-world evidence • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol. (PubMed, J Ocul Pharmacol Ther) - P4 | "No AHD differences were linked to the timolol response. Timolol nonresponders were often responsive to latanoprost, but not vice versa."

Journal • Glaucoma • Ophthalmology

Ketorolac, melatonin and latanoprost tri-loaded PLGA microspheres for neuroprotection in glaucoma. (PubMed, Drug Deliv) - "Treated glaucomatous rats reached the lowest intraocular pressure, enhanced functionality of bipolar and retinal ganglion cells and showed greater neuroretinal thickness by optical coherence tomography (p < 0.05) compared to not treated glaucomatous rats at 24 weeks follow-up. According to the results, the tri-loaded microspheres can be considered as promising controlled-release system for the treatment of glaucoma."

Journal • CNS Disorders • Glaucoma • Ophthalmology

Periorbital skin hypopigmentation associated with the use of topical glaucoma medications. (PubMed, Digit J Ophthalmol) - "Timolol and brinzolamide/brimonidine have not been associated with changes in skin pigmentation in the ophthalmic literature. Our case most likely represents a rare instance of paradoxical skin depigmentation associated with latanoprost use and adds to the limited literature on this clinical entity."

Journal • Cardiovascular • Glaucoma • Ophthalmology

CARDIOVASCULAR ADVERSE EVENTS ASSOCIATED WITH ANTIGLAUCOMA MEDICATIONS: A PHARMACOVIGILANCE STUDY OF THE FDA ADVERSE EVENT REPORTING SYSTEM - Abhishek Kandukuru (ACC 2025) - "Background: This study investigates the pharmacovigilance of cardiovascular adverse events (AEs) linked to three antiglaucoma medications: Acetazolamide, Latanoprost, and Travoprost. The study's key findings indicate significant associations between cardiovascular adverse events and the use of certain antiglaucoma medications. These findings underscore the need for careful cardiovascular monitoring in patients using these medications. Understanding safety signals and the effects between such drugs and cardiovascular events allows informing therapeutic practices and improving the safety of patients in practice."

Adverse events • Cardiovascular • Congestive Heart Failure • Glaucoma • Heart Failure • Ophthalmology

OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects (clinicaltrials.gov) - P3 | N=204 | Completed | Sponsor: Otsuka Beijing Research Institute | Recruiting ➔ Completed | Trial completion date: Apr 2024 ➔ Dec 2024 | Trial primary completion date: Mar 2024 ➔ Nov 2024

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

Effects of Brimonidine, Latanoprost, and Omidenepag on Tunicamycin-Induced Endoplasmic Reticulum Stress and Fibrosis in Human Trabecular Meshwork Cells. (PubMed, Biomolecules) - "In addition, COL1A1 mRNA expression was significantly lowered with LAT or OMD cotreatment compared to the BRI-cotreated group. Cotreatment with α2-adrenergic agonist, prostaglandin F2α analog, or EP2 receptor agonist alleviates tunicamycin-induced ER stress in human TM cells."

Journal • Fibrosis • Immunology • COL1A1 • CTGF • HSPA5 • XBP1

PEG-coated nanoparticles to sustain drug release for ophthalmic drug delivery (ARVO 2025) - "To assess loading capacity and release profile, dexamethasone (DEX) and latanoprost (LTP) were encapsulated...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Modelling intraocular pressure as time-varying in actively managed glaucoma reveals its impact on the true rate of visual field progression (ARVO 2025) - "Methods In UKGTS, patients with glaucoma were randomized to placebo or Latanoprost drops and monitored for up to 2 years...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Glaucoma • Ophthalmology